Developing a Bispecific anti-VEGF/Complement C3 Inhibitor to Treat nAMD & Macular Atrophy

Time: 11:00 am
day: Day One


  • Wet AMD patients with anti-VEGF therapies develop geographic atrophy
  • A combination of VEGF and C3 inhibition may result in superior outcome in wet AMD patients
  • Novel endpoints are needed to assess the functional benefits of GA therapies